These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia. Uvais NA Prim Care Companion CNS Disord; 2020 Apr; 22(3):. PubMed ID: 32369686 [No Abstract] [Full Text] [Related]
5. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given. Malviya A Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688 [No Abstract] [Full Text] [Related]
6. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits. Halm MA Am J Crit Care; 2020 Nov; 29(6):489-492. PubMed ID: 32839815 [No Abstract] [Full Text] [Related]
7. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. Peschken CA J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064 [No Abstract] [Full Text] [Related]
8. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. Scuccimarri R; Sutton E; Fitzcharles MA J Rheumatol; 2020 Jun; 47(6):783-786. PubMed ID: 32241801 [No Abstract] [Full Text] [Related]
9. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]. Defoort-Dhellemmes S J Fr Ophtalmol; 2020 Jun; 43(6):548-549. PubMed ID: 32451138 [No Abstract] [Full Text] [Related]
10. Regulators split on antimalarials for COVID-19. Jaffe S Lancet; 2020 Apr; 395(10231):1179. PubMed ID: 32278373 [No Abstract] [Full Text] [Related]
11. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Nina PB; Dash AP Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241 [TBL] [Abstract][Full Text] [Related]
12. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks. Yahya AS; Khawaja S; Chukwuma J Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32441496 [No Abstract] [Full Text] [Related]
14. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness]. Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic conflict in patients with COVID-19 and glaucoma. Millá Griñó E; Muniesa Royo MJ; Pazos López M Med Clin (Barc); 2020 Aug; 155(4):182. PubMed ID: 32591182 [No Abstract] [Full Text] [Related]
16. The coronavirus outbreak could make it quicker and easier to trial drugs. Ledford H Nature; 2020 Jun; 582(7811):172. PubMed ID: 32504019 [No Abstract] [Full Text] [Related]
17. [Potential harms associated with 4-aminoquinoline treatment]. Svensson M Lakartidningen; 2020 Apr; 117():. PubMed ID: 32365215 [TBL] [Abstract][Full Text] [Related]
18. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine]. Tomcsányi J; Tomcsányi K Orv Hetil; 2020 Apr; 161(17):689-691. PubMed ID: 32324363 [TBL] [Abstract][Full Text] [Related]
19. Acute meningoencephalitis in a patient with COVID-19. Chaumont H; Etienne P; Roze E; Couratier C; Roger PM; Lannuzel A Rev Neurol (Paris); 2020 Jun; 176(6):519-521. PubMed ID: 32414534 [No Abstract] [Full Text] [Related]
20. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. Harrigan JJ; Hubbard RA; Thomas S; Riello RJ; Bange E; Mamtani M; Mamtani R J Gen Intern Med; 2020 Sep; 35(9):2826-2828. PubMed ID: 32542496 [No Abstract] [Full Text] [Related] [Next] [New Search]